Opioid Substitution Treatment (OST) - Treatment Guidelines & Switching Methadone to Buprenorphine

1. Overview of OST for Opioid Dependence Syndrome

• Harm minimisation (e.g., take-home naloxone)
• Maintenance OST with methadone or buprenorphine
• Naltrexone for relapse prevention (though patient acceptability is low)

• Reduce or eliminate illicit opioid use
• Reduce drug-related harm (especially injecting)
• Stabilise drug intake and lifestyle
• Engage the patient in a therapeutic relationship

Key safety principle: OST can be fatal; opioid withdrawal is not life-threatening. The risk of opioid toxicity must be weighed against the risk of self-discharge - which carries an eightfold increased probability of drug-related death in the 2 days following self-discharge.

2. Pre-OST Assessment

• Physiological dependence on opioids (clinical evidence of withdrawal + positive UDS if possible)
• Which opioids are being used and in what amounts
• Concomitant use of alcohol, benzodiazepines, gabapentinoids
• Physical comorbidities (COPD, cardiac conditions - especially for methadone/QT)
• Prescribed medications (interactions with OST - e.g., QT-prolonging drugs)
• Previous treatment history and overdoses
• Availability of take-home naloxone
• Objective assessment with COWS (Clinical Opiate Withdrawal Scale) or OOWS (Objective Opiate Withdrawal Scale)

3. Choosing Between Methadone and Buprenorphine

4. Methadone Induction

• Initiation in a community setting should be supervised consumption (daily dispensing, observed)
• Starting dose: 10-30 mg depending on tolerance assessment
• Increase by 5-10 mg every few days until stabilisation
• Therapeutic target: 60-100 mg/day
• Titration phase carries highest mortality risk - titrate slowly over several weeks
• Monitor for QT prolongation - baseline ECG recommended, especially if >100 mg/day or other QT-prolonging agents used

5. Buprenorphine Induction

• Patient in withdrawal, no risk factors: 8 mg
• Patient not in withdrawal, no risk factors: 4 mg
• Risk factors present (medical comorbidity, polydrug use, uncertain dependence severity, psychiatric medications): 2-4 mg
• Do not exceed 8 mg on day 1 in non-specialist settings
• Day 2: increase to 12-16 mg if no intoxication

6. Switching from Methadone to Buprenorphine

Approach depends on current methadone dose:

A. Methadone dose ≤30 mg/day (Standard Transfer)

1. Either stop methadone abruptly or taper to ≤30 mg (evidence does not favour one approach over the other)
2. Wait 48-96 hours after the last methadone dose until clear signs of withdrawal are present (COWS ≥8-12)
3. Give initial buprenorphine 2-4 mg
4. Review after 2-3 hours:
   • If withdrawal precipitated or worsened: symptomatic treatment (loperamide, clonidine, NSAIDs, antiemetics)
   • If no precipitation: give additional 2-4 mg same day
5. Next day: increase to 8-12 mg
6. Subsequent days: titrate up to therapeutic maintenance dose (12-24 mg)

B. Methadone dose >60 mg/day (High-Dose Transfer)

• Do NOT attempt in outpatient setting except in exceptional circumstances by an experienced practitioner
• Refer to a dedicated addictions in-patient unit
• Partially detoxify from methadone first, transfer only when dose is at or below 30 mg/day

C. Low-Dose (Micro-Dose) Induction Protocol (for patients unable to wait for withdrawal)

7. Prolonged-Release (Depot) Buprenorphine

8. Maintenance Dose Targets

• Methadone: 60-100 mg/day (supervised consumption initially; QT monitoring)
• Buprenorphine SL: 12-24 mg/day
• Buprenorphine/naloxone (Suboxone): preferred over mono-buprenorphine to reduce diversion risk

9. Managing Withdrawal During Detoxification

Methadone detoxification

• Reduce by 5-10 mg weekly or fortnightly
• Towards end: slow to 1-2 mg per week
• In-patient: can complete over up to 4 weeks
• Longer stability periods and prolonged reduction schedules (up to 1 year) substantially improve abstinence outcomes

Buprenorphine detoxification

10. Naltrexone for Relapse Prevention

• For patients who complete opioid detoxification and prefer abstinence
• NICE: cost-effective when patient is highly motivated and has a partner supporting adherence
• Caution: Naltrexone cessation is associated with a 3-fold increased mortality relative to methadone (Australian data), almost entirely from overdose
• Close monitoring at initiation and discontinuation is mandatory

11. Recent Evidence (2024-2026)

Latest 2024-2026 Clinical Practice Guidelines for Opioid Dependence Management

1. CRISM Canada - 2024 National Clinical Practice Guideline Update

Core Recommendations:

• Methadone and buprenorphine are now both considered equally preferred first-line treatment - the 2018 guideline had favoured buprenorphine; the 2024 update recognises equivalent efficacy in reducing opioid use and adverse events
• Slow-release oral morphine (SROM) is recommended as a second-line option when first-line agents are contraindicated or not tolerated
• Psychosocial interventions (CBT, motivational interviewing) may be offered as adjunctive therapy but are no longer mandatory - pharmacotherapy alone is sufficient
• Harm reduction services (take-home naloxone, needle/syringe programmes) should be integrated along the entire continuum of care
• Withdrawal management as a standalone intervention is not recommended - it is insufficient and leads to high relapse and overdose mortality
• Graded using GRADE methodology; multidisciplinary panel including people with lived experience

2. British Association for Psychopharmacology (BAP) - 2026 Consensus Guidelines

Key Opioid Recommendations:

• Opioid substitution treatment (OST) with methadone or buprenorphine is the first-line approach - preferred over immediate withdrawal management
• Long-acting injectable (depot) buprenorphine is highlighted as a significant newer option, improving adherence and reducing diversion risk
• Take-home naloxone (THN) must be provided to all opioid users and their support networks, with training
• Naltrexone may help prevent relapse after discontinuation of OST, but carries risk - patients must be fully informed
• Emphasises shared decision-making and integrating pharmacological treatment with psychosocial care

3. ASAM National Practice Guideline - 2020 (still current; 2025 Hospital Implementation Update)

• All three FDA-approved medications (methadone, buprenorphine/naloxone, naltrexone) are recommended as first-line
• Methadone for OUD must be dispensed through a federally licensed opioid treatment programme (OTP)
• Buprenorphine can be initiated in any setting, including primary care, emergency departments, and hospitals
• Emergency department initiation of buprenorphine is supported with strong evidence and is actively encouraged (JAMA 2025 data confirming downstream prescription continuity)

4. SOGC Guideline No. 443b - Opioid Use in Pregnancy (2023)

• Buprenorphine/naloxone is preferred over methadone in pregnancy (lower neonatal opioid withdrawal syndrome severity)
• OST should be continued or initiated in pregnancy - abrupt discontinuation is harmful
• Fetal monitoring and dose adjustments are required in second/third trimester

5. Key Supporting Evidence 2025-2026

Meta-Analysis: Buprenorphine-Naloxone vs Methadone

Clinical implication: Methadone = better retention; buprenorphine-naloxone = better safety profile. Treatment choice should be individualised.

Expert Review: Approved Medications 2025 Update

• Oral methadone and buprenorphine remain the gold standard first-line agents
• Depot buprenorphine (Buvidal weekly/monthly; Sublocade) improves adherence and clinical management
• Diacetylmorphine (heroin-assisted treatment, HAT) and slow-release oral morphine (SROM/Kadian) are second-line for treatment-refractory patients
• Future focus: identifying responder characteristics for individual medications

Systematic Review: Benzodiazepine Co-Prescription and OAT Mortality

• Benzodiazepine co-prescription in patients on OAT is associated with significantly increased mortality
• Co-prescribing should be avoided or minimised where possible

Summary of Key 2024-2026 Guideline Shifts

OST Options for a Patient Who Cannot Attend Daily for Methadone

Why Daily Supervised Methadone is Required Initially

• Tolerance can be lost in a matter of days
• Highest mortality risk is during the titration phase
• Risk of diversion to others (including children in the household)

Option 1: Take-Home (Unsupervised) Methadone - Reduced Attendance

Criteria for granting take-home methadone doses (UK "Orange Book" / NICE / ASAM):

• Clinically stable on methadone (no dose changes needed for several weeks)
• Not using illicit opioids (confirmed by urine drug screens)
• Not misusing other substances (particularly benzodiazepines, alcohol - these greatly increase overdose risk with methadone)
• No active psychiatric instability
• Safe, supervised storage at home (no young children, no cohabitants who could access medication)
• Engaged with treatment and attending appointments
• No evidence of diversion of previous take-home doses

Dispensing schedules typically progress:

Important: The clinician specifies dispensing frequency on the prescription (e.g., "daily supervised" or "3-day supply"). This must be actively reviewed and documented. During the COVID-19 pandemic, take-home policies were relaxed significantly, and evidence showed this was generally safe in stable patients.

Option 2: Switch to Buprenorphine/Naloxone (Suboxone) - Best Practical Option for Working Patients

Why buprenorphine is safer for take-home:

• Partial agonist with a ceiling effect on respiratory depression - much harder to fatally overdose compared to methadone
• Higher receptor affinity means it is not easily displaced by other opioids (reduces risk from diversion/misuse)
• Naloxone component discourages injection misuse
• Evidence shows no increase in buprenorphine-related deaths above expected trends when daily supervised consumption is replaced with take-home dosing (unlike methadone, which shows increased deaths)

Take-home protocol:

• Can be given as weekly or fortnightly supplies in stable patients
• No daily pharmacy attendance required once stable
• Taken once daily sublingually (long half-life, 24-72 hrs)
• Maintenance dose: 12-24 mg/day

The 2026 BAP guideline and 2024 CMAJ guideline both confirm:

• Buprenorphine and methadone are equally preferred first-line agents
• For patients where daily attendance is a barrier, buprenorphine/naloxone is the preferred practical choice

Option 3: Depot (Long-Acting Injectable) Buprenorphine - Ideal for Compliance Issues

Available formulations:

Dose equivalence (Maudsley 15th ed., Table 4.15):

Clinical evidence for depot buprenorphine:

• A 2026 network meta-analysis (Kabra et al., PMID: 41521864) of 98 studies found monthly injectable buprenorphine showed the highest likelihood of treatment retention and avoidance of illicit opioid use compared to methadone, oral buprenorphine, and other formulations
• A superiority RCT showed ~70% sustained abstinence at 18 months - the longer the period on depot, the higher the abstinence rate
• Better quality of life scores compared to daily oral formulations
• Reduces peaks and troughs experienced with sublingual dosing
• Eliminates diversion risk entirely

Contraindications to depot buprenorphine:

• Hypersensitivity to buprenorphine or excipients
• Severe hepatic impairment
• Alcohol dependence with delirium tremens

Adoption:

Option 4: Slow-Release Oral Morphine (SROM/Kadian)

Practical Decision Algorithm for a Working Patient

Patient stable on methadone but cannot attend daily?
         |
         ├── Already stable ≥4-8 weeks, no illicit use, safe storage?
         │         → REDUCE DISPENSING FREQUENCY (take-home methadone)
         │           Progress to weekly/fortnightly as stability continues
         |
         ├── Prefers fewer pharmacy visits long-term / concerned about methadone risks?
         │         → SWITCH TO BUPRENORPHINE/NALOXONE (daily oral, weekly take-home)
         |
         └── Maximum convenience needed / compliance concerns / work travel / stigma?
                   → DEPOT BUPRENORPHINE INJECTION (weekly or monthly)
                     Best evidence for retention and abstinence (2026 data)

Summary Table